BCMA/TNFRSF17 Antibody (CD269/8190R)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-20456

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Kappa Clone # CD269/8190R

Concentration

0.2 mg/ml

View all BCMA/TNFRSF17 Antibodies »

Product Specifications

Immunogen

Recombinant human BCMA/TNFRSF17 protein fragment (around aa 1-184) (exact sequence is proprietary)

Localization

Cell surface.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG Kappa

Description

Positive Controls: NAMALWA cells. Tonsil or gastric carcinoma (IHC).

Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C. Non-hazardous. No MSDS required.

Scientific Data Images for BCMA/TNFRSF17 Antibody (CD269/8190R)

BCMA/TNFRSF17 Antibody (CD269/8190R)

BCMA/TNFRSF17 Antibody (CD269/8190R)

Formalin-fixed, paraffin-embedded human tonsil stained with BCMA/TNFRSF17 antibody (CD269/8190R). HIER: Tris/EDTA, pH9.0, 45min. Secondary: HRP-polymer, 30min. DAB, 5min.

Applications for BCMA/TNFRSF17 Antibody (CD269/8190R)

Application
Recommended Usage

Immunohistochemistry-Paraffin

1-2 ug/ml
Application Notes
ELISA: For coating, order antibody without BSA

Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes. at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.

Optimal dilution for a specific application should be determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

10mM PBS with 0.05% BSA

Preservative

0.05% Sodium Azide

Concentration

0.2 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: BCMA/TNFRSF17

B cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a type III transmembrane glycoprotein that plays a role in B cell maturation and differentiation into plasma cells and is a therapeutic target for treatment of multiple myeloma (MM) (1,2). BMCA is synthesized as a protein of 184 amino acids (aa) in length with a theoretical molecular weight of 20.2 kDa consisting of an extracellular N-terminus containing 6 cysteine residues, a transmembrane domain, and an intracellular tumor necrosis factor (TRAF) binding domain (1). BCMA is functionally similar to two other TNFR superfamily members, B cell activation factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (1,2). BCMA is primarily expressed on plasmablasts, plasma cells, and late-stage B cells (1,2).

BCMA has two agonistic ligands: BAFF and a proliferation-inducing ligand (APRIL) (1,2). APRIL has higher affinity for BCMA than BAFF and the binding is mediated by CD138/syndeclin-1 (2,3). Activation of BCMA promotes the growth and survival of plasma cells, or MM cells in disease, through several signaling pathways such as NFkappaB, MEK/ERK, AKT, JNK, and p38 (1,2). In MM cells the BCMA activation and downstream signaling cascade functions to upregulate antiapoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 and protect the cells against therapeutic agents like dexamethasone (2,3).

Given its specific expression on plasma cells but not memory B cells, naive B cells, or hematopoietic stem cells, BCMA has garnered much interest as a therapeutic target for the treatment of MM (1-4). Current BCMA-targeted immunotherapy strategies include antibody-drug conjugates (ADC), chimeric antigen receptor (CAR) T cells, bispecific T cell engager (BiTE), and bispecific/trispecific antibodies (1-4). CAR T cell therapy in particular has demonstrated promising clinical results (2,4). Still, more research needs to be done to improve the efficacy and risk of relapse following CAR T cell therapy and may also include targeting additional antigens in combination with BCMA or utilizing pharmacological agents to increase antigen density (4).

References

1. Yu, B., Jiang, T., & Liu, D. (2020). BCMA-targeted immunotherapy for multiple myeloma. Journal of hematology & oncology, 13(1), 125. https://doi.org/10.1186/s13045-020-00962-7

2. Cho, S. F., Anderson, K. C., & Tai, Y. T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in immunology, 9, 1821. https://doi.org/10.3389/fimmu.2018.01821

3. Dalla Palma, B., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020). Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of clinical medicine, 9(9), 3022. https://doi.org/10.3390/jcm9093022

4. Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature reviews. Clinical oncology, 18(2), 71-84. https://doi.org/10.1038/s41571-020-0427-6

Long Name

B Cell Maturation Factor

Alternate Names

CD269, TNFRSF13A, TNFRSF17

Gene Symbol

TNFRSF17

UniProt

Q02223

Additional BCMA/TNFRSF17 Products

Product Documents for BCMA/TNFRSF17 Antibody (CD269/8190R)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for BCMA/TNFRSF17 Antibody (CD269/8190R)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.